Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIFD35)

Drug Name
Inositol 1,3,4,5-Tetrakisphosphate Drug Info
Synonyms
inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
107758
ChEBI ID
CHEBI:16783
CAS Number
CAS 102850-29-3
TTD Drug ID
DMIFD35
INTEDE Drug ID
DR2090

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tyrosine-protein kinase BTK (ATK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibrutinib DMHZCPO Mantle cell lymphoma 2A85.5 Approved [4]
Acalabrutinib DM7GCVW leukaemia 2A60-2B33 Approved [5]
Zanubrutinib DMJWRQP Mantle cell lymphoma 2A85.5 Approved [6]
Pirtobrutinib DMRG1X3 Non-hodgkin lymphoma 2B33.5 Approved [7]
GDC-0853 DMBEL3Q Multiple sclerosis 8A40 Phase 3 [8]
ICP-022 DMU72KL Chronic lymphocytic leukaemia 2A82.0 Phase 3 [9]
Tolebrutinib DML19V6 Multiple sclerosis 8A40 Phase 3 [10]
CC-292 DMJR9H0 Chronic lymphocytic leukaemia 2A82.0 Phase 2 [11]
BMS-986142 DMZB8AJ Rheumatoid arthritis FA20 Phase 2 [8]
LOU064 DME8O5K Chronic idiopathic urticaria EB00.1 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Capivasertib DM9SKW8 Breast cancer 2C60-2C65 Approved [13]
Enzastaurin DM5H0R9 Diffuse large B-cell lymphoma 2A81 Phase 3 [13]
GDC-0068 DMWBZJD Breast cancer 2C60-2C65 Phase 3 [13]
CI-1033 DMSI8N3 Lymphoma 2A80-2A86 Phase 2 [14]
CMX-2043 DMPSCVY Cardiac disease BA00-BE2Z Phase 2 [15]
ARQ 092 DM5WK0J Proteus syndrome LD2C Phase 2 [16]
GSK2110183 DMZHB37 leukaemia 2A60-2B33 Phase 2 [17]
RX-0201 DMTBAV3 Pancreatic cancer 2C10 Phase 2 [18]
PTX-200 DM0ZIT2 Breast cancer 2C60-2C65 Phase 2 [13]
Triciribine prodrug DMBN1XS Solid tumour/cancer 2A00-2F9Z Phase 1/2 [17]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
RAC-alpha serine/threonine-protein kinase (AKT1) TTWTSCV AKT1_HUMAN Inhibitor [2]
Tyrosine-protein kinase BTK (ATK) TTGM6VW BTK_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Inositol tetrakisphosphate 3-phosphatase (MIPP) Main DME DE5Q1SP MINP1_HUMAN Substrate [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5202).
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 The human and rat forms of multiple inositol polyphosphate phosphatase: functional homology with a histidine acid phosphatase up-regulated during endochondral ossification. FEBS Lett. 1999 Jan 8;442(1):99-104.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
5 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
7 Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of InnoCare Pharma.
10 Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
11 Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
15 Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
18 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.